{
    "clinical_study": {
        "@rank": "67298", 
        "arm_group": {
            "arm_group_label": "Device Applied", 
            "arm_group_type": "Experimental", 
            "description": "All participants will be treated with the Angioshield"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether or not the Angioshield device can be\n      safely applied to support saphenous vein grafts used in standard coronary bypass surgery."
        }, 
        "brief_title": "Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "\\This is a first in human study which is intended to determine if a larger pivotal study is\n      justified."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subject will be eligible for inclusion in the investigation if he/she:\n\n          -  is between the ages of 18 and 80 years of age, inclusive\n\n          -  requires Coronary Atery Bypass Graft (CABG) surgery with minimum of one SVG used to\n             bypass a stenosis in the Right Coronary, the Circumflex, a Diagonal, or an Obtuse\n             Marginal artery, due to atherosclerotic coronary artery disease\n\n          -  is able to give their informed written consent\n\n          -  is willing and able to complete all follow-up visits and procedures\n\n        Exclusion Criteria:\n\n        Subject will be excluded from participation in the investigation if he/she:\n\n          -  is currently enrolled in another clinical investigation\n\n          -  is unable to tolerate or comply with required post-surgical medications or imaging\n             (e.g., anticoagulation regimen; or known allergy to contrast agent)\n\n          -  is or may be pregnant or is lactating, or plans to become pregnant in the next 12\n             months\n\n          -  shows a presence of hypercoagulable state or history of idiopathic venous or arterial\n             thrombosis\n\n          -  has had an acute MI within the last 21 days\n\n          -  has had a previous CABG\n\n          -  requires emergency surgery\n\n          -  has a left ejection fraction (LEF) less than 20%\n\n          -  has a  target vessel stenosis of less than 70%\n\n          -  has a transmural infarct of the  target artery territory\n\n          -  currently requiring dialysis\n\n          -  is having concomitant-surgery of any kind\n\n          -  has varicose veins\n\n          -  has had previous saphenectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072239", 
            "org_study_id": "TP11-002"
        }, 
        "intervention": {
            "arm_group_label": "Device Applied", 
            "description": "The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.", 
            "intervention_name": "Angioshield", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CABG", 
            "Intimal Hyperplasia", 
            "Atherosclerosis", 
            "Myocardial Infarction"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "last_name": "Jerzy Sadowski, MD, PhD", 
                "phone": "48 12 614 30 75"
            }, 
            "facility": {
                "address": {
                    "city": "Krakow", 
                    "country": "Poland"
                }, 
                "name": "Pope John Paul II Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Bogus\u0142aw Kapelak, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Krzysztof Bartus, Md, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "1", 
        "official_title": "First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery", 
        "overall_official": {
            "affiliation": "Pope John Paul II Hospital and Cardiology Collegium Medicum Jagiellonian University, Krakow, Poland", 
            "last_name": "Jerzy Sadowski, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to provide acute and subacute (up to 30 days) safety outcomes to support expansion to a pivotal study involving a larger subject population.  All Major Adverse Cardiac Events (MACE), defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization, will be evaluated at 30 days post-operative.", 
            "measure": "MACE", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objective of this study is to assess long term (up to 1 year) safety outcomes and vein patency for additional safety and preliminary efficacy information.  All MACE, defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization will be evaluated at 90 and 365 days and to assess patency of the treated saphenous vein graft at 30, 90 and 365 days", 
            "measure": "MACE and Graft Patency", 
            "safety_issue": "Yes", 
            "time_frame": "30, 90 and 365 Days"
        }, 
        "source": "Neograft Technologies, Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neograft Technologies, Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}